Gossamer Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Gossamer Bio, Inc. (Nasdaq: GOSS) on March 11, 2024. The report discloses corporate governance changes involving the appointment of two new independent directors to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on director appointments and associated compensation arrangements.
Material Changes
On March 11, 2024, the Board of Directors appointed two new independent directors:
- Skye Drynan: Appointed as a Class III director with a term expiring at the 2024 annual meeting. She brings experience as the Founder/CEO of House of Skye, Ltd., and a former Senior BioPharma Analyst at Capital Group.
- Steven Nathan, M.D.: Appointed as a Class I director with a term expiring at the 2025 annual meeting. He is a board-certified physician and Medical Director of Inova Health System's Advanced Disease Program.
Compensation and Governance Details
Pursuant to the non-employee director compensation program, both appointees received:
- An annual cash retainer of $40,000.
- An option to purchase 230,000 shares of common stock, vesting monthly over three years.
- Standard indemnification agreements.
The Board determined both individuals meet the independence requirements of the Nasdaq Global Select Market. A press release announcing these appointments was issued on March 12, 2024.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 230,000 stock options granted to each new director.
- Confirm the specific expiration dates for the Class I and Class III director terms at the upcoming annual meetings.
- Review the full press release (Exhibit 99.1) for additional biographical details or strategic rationale for the appointments.
- Check subsequent filings for any changes to the Board composition or compensation policies.